CVS Health Corporation (NYSE:CVS)‘s stock had its “outperform” rating reaffirmed by research analysts at Robert W. Baird in a research note issued on Monday. They presently have a $90.00 target price on the pharmacy operator’s stock. Robert W. Baird’s price target would suggest a potential upside of 13.49% from the stock’s current price.

Other analysts have also recently issued reports about the stock. Wolfe Research cut shares of CVS Health Corporation from an “outperform” rating to a “market perform” rating in a research report on Monday. Vetr cut shares of CVS Health Corporation from a “buy” rating to a “hold” rating and set a $85.78 price target for the company. in a research report on Thursday, April 27th. Cowen and Company reaffirmed an “outperform” rating and set a $86.00 price target on shares of CVS Health Corporation in a research report on Tuesday, June 13th. BidaskClub raised shares of CVS Health Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Leerink Swann set a $90.00 price target on shares of CVS Health Corporation and gave the stock a “buy” rating in a research report on Tuesday, June 27th. Eight analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $92.04.

Get CVS Health Corporation alerts:

Shares of CVS Health Corporation (CVS) traded down 0.14% during mid-day trading on Monday, hitting $79.30. The stock had a trading volume of 3,800,570 shares. The stock has a market cap of $80.61 billion, a P/E ratio of 15.80 and a beta of 0.91. The company’s 50 day moving average price is $78.89 and its 200 day moving average price is $78.94. CVS Health Corporation has a 12-month low of $69.30 and a 12-month high of $98.44.

CVS Health Corporation (NYSE:CVS) last announced its quarterly earnings data on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.31 by $0.02. CVS Health Corporation had a net margin of 2.93% and a return on equity of 17.47%. The company had revenue of $45.69 billion during the quarter, compared to analysts’ expectations of $45.36 billion. During the same period in the previous year, the company earned $1.32 EPS. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. Equities research analysts predict that CVS Health Corporation will post $5.88 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/14/cvs-health-corporation-cvs-receives-outperform-rating-from-robert-w-baird.html.

In other news, EVP Helena Foulkes sold 20,333 shares of the company’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $80.00, for a total value of $1,626,640.00. Following the sale, the executive vice president now owns 59,301 shares in the company, valued at approximately $4,744,080. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO David M. Denton sold 230,510 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $80.00, for a total transaction of $18,440,800.00. Following the completion of the sale, the chief financial officer now owns 176,983 shares in the company, valued at approximately $14,158,640. The disclosure for this sale can be found here. In the last 90 days, insiders sold 271,175 shares of company stock worth $21,632,597. Company insiders own 0.61% of the company’s stock.

Several large investors have recently modified their holdings of the stock. Creative Planning raised its stake in shares of CVS Health Corporation by 1.5% in the first quarter. Creative Planning now owns 90,927 shares of the pharmacy operator’s stock worth $7,138,000 after buying an additional 1,321 shares during the period. S&CO Inc. raised its stake in shares of CVS Health Corporation by 2.1% in the first quarter. S&CO Inc. now owns 7,435 shares of the pharmacy operator’s stock worth $584,000 after buying an additional 150 shares during the period. Raymond James Trust N.A. raised its stake in shares of CVS Health Corporation by 10.2% in the first quarter. Raymond James Trust N.A. now owns 124,748 shares of the pharmacy operator’s stock worth $9,793,000 after buying an additional 11,558 shares during the period. Osborn Williams & Donohoe LLC raised its stake in shares of CVS Health Corporation by 2.2% in the first quarter. Osborn Williams & Donohoe LLC now owns 99,469 shares of the pharmacy operator’s stock worth $7,808,000 after buying an additional 2,158 shares during the period. Finally, Indiana Trust & Investment Management CO raised its stake in shares of CVS Health Corporation by 2.7% in the first quarter. Indiana Trust & Investment Management CO now owns 19,744 shares of the pharmacy operator’s stock worth $1,550,000 after buying an additional 510 shares during the period. Institutional investors and hedge funds own 82.31% of the company’s stock.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.